Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)

Subscribe to Selected New Research on Mucocutaneous Lymph Node Syndrome

1156 relevant articles (61 outcomes, 133 trials/studies) found for this Disease

Description: An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.

Also Known As:

Kawasaki Disease; MCLS; Disease, Kawasaki; Lymph Node Syndrome, Mucocutaneous

Relationship Network

Disease Context: Research Results

Cardiovascular Diseases: 20552

Vascular Diseases: 7633

Vasculitis: 6757

Mucocutaneous Lymph Node Syndrome: 1156

Hemic and Lymphatic Diseases

Lymphatic Diseases: 1961

Mucocutaneous Lymph Node Syndrome: 1156

Skin and Connective Tissue Diseases

Skin Diseases: 6187

Vascular Skin Diseases: 2

Mucocutaneous Lymph Node Syndrome: 1156

Related Diseases

1.	Syndrome
2.	Aneurysm (Aneurysms)
3.	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease)
4.	Vasculitis (Vasculitides)
5.	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)

Experts

1.	Shulman, Stanford T: 12 articles (01/2008 - 02/2002)
2.	Rowley, Anne H: 10 articles (01/2008 - 02/2002)
3.	Burns, Jane C: 8 articles (07/2008 - 06/2005)
4.	Tsuda, Etsuko: 8 articles (03/2008 - 06/2003)
5.	Terai, Masaru: 7 articles (05/2005 - 02/2002)
6.	Miura, Masaru: 6 articles (10/2008 - 01/2004)
7.	Newburger, Jane W: 6 articles (07/2008 - 06/2003)
8.	Kitamura, Soichiro: 6 articles (03/2008 - 06/2003)
9.	Li, Cheng-rong: 6 articles (01/2008 - 08/2003)
10.	Garcia, Francesca L: 6 articles (01/2008 - 04/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mucocutaneous Lymph Node Syndrome:

1.	gamma-Globulins (gamma-Globulin)IBA 04/01/2003 - "Following the standard treatment with intravenous gamma globulin, the initial symptoms and signs of Kawasaki disease resolved completely. " 03/01/1995 - "However, high-dose intravenous gamma-globulin (IVGG) is a safe and effective treatment for Kawasaki disease. " 08/01/2000 - "OBJECTIVE: We evaluated the efficacy of intravenous gamma-globulin (IVGG) administration for children with Kawasaki disease to establish whether additional, more advanced therapy is needed in intractable cases. " 06/06/1991 - "In children with acute Kawasaki disease, a single large dose of intravenous gamma globulin is more effective than the conventional regimen of four smaller daily doses and is equally safe." 12/01/1997 - "The efficacy of intravenous gamma globulin (IVGG) for treatment of Kawasaki disease (KD) is clearly established. " Order ALL the reference details at left...
2.	Intravenous Immunoglobulins (IVIG)FDA Link 05/01/2002 - "Although the exact mode of action is still poorly understood, the efficacy of IVIg in several diseases, such as thrombocytopenic pupura and Kawasaki disease, has been proven in clinical trials. " 08/01/2003 - "CONCLUSION: The efficacy of a high dose (2 g/kg) of Thai Red-Cross IVIG in Kawasaki disease is excellent. " 10/01/1989 - "High-dose intravenous immune globulin treatment is effective in preventing the occurrence of coronary artery abnormalities in Kawasaki disease. " 07/01/2009 - "IVIG reduced vascular oxidative stress in patients with Kawasaki disease." 02/01/2009 - "Approximately 15-20% of patients with Kawasaki disease (KD) are not responsive to high-dose intravenous gammaglobulin (IVIG). " Order ALL the reference details at left...
3.	Immunoglobulins (Immunoglobulin)IBA 02/01/2008 - "High-dose intravenous immunoglobulin (VIG) treatment for the acute stage of Kawasaki disease (KD) has shown to be effective and safe. " 06/01/2009 - "More than half of the patients with acute Kawasaki disease, nonetheless, can be cured by giving only 1 gram per kilogram of immunoglobulin, thus reducing this aspect of the cost of treatment by half. " 11/01/1994 - "The mechanism of efficacy of intravenous immunoglobulin in Kawasaki disease." 12/12/1990 - "[Intravenous administration of immunoglobulin speeds up improvement in Kawasaki disease]" 07/01/2009 - "We analyzed data for patients with (1) a diagnosis code for Kawasaki disease, (2) intravenously administered immunoglobulin treatment during hospitalization, and (3) discharge between January 1, 2001, and December 30, 2006, from 27 hospitals contributing complete data over the study period. " Order ALL the reference details at left...
4.	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/01/1990 - "The effects of intravenous gammaglobulin (IVGG) on changes in the peripheral blood mononuclear cell subsets during acute Kawasaki disease (KD) were studied by a random selection trial of IVGG plus Aspirin (group G) compared to Aspirin alone (group A). " 02/01/1988 - "Studies on the effect of long-term use of low dose aspirin in Kawasaki disease." 05/01/1987 - "To evaluate the effectiveness of gammaglobulin in decreasing the incidence of coronary artery lesions in Kawasaki disease, a randomized controlled study in 136 patients was conducted using high doses of gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d (gammaglobulin group) and aspirin alone at the same dosage (aspirin group). " 11/10/1984 - "The ability of high-dose intravenous gammaglobulin (IVGG) to prevent the coronary artery lesion of Kawasaki disease has been studied in a multicentre controlled trial of IVGG plus aspirin versus aspirin alone, aspirin being the conventional treatment for Kawasaki disease. " 03/01/2006 - "[Interpretation of aspirin plasma concentration in the acute phase of Kawasaki disease]" Order ALL the reference details at left...
5.	Adrenal Cortex Hormones (Corticosteroids)IBA 07/01/2009 - "METHODS: We included randomised trials comparing the addition of corticosteroids to conventional primary therapy for Kawasaki disease. " 09/01/2006 - "A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome." 06/01/2003 - "Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial." 10/01/1999 - "OBJECTIVES: Corticosteroids are considered to be contraindicated during the acute phase of Kawasaki disease (KD) based on unfavorable results in early studies. " 07/01/2007 - "Pulsed corticosteroids of no benefit in Kawasaki disease." Order ALL the reference details at left...
6.	CytokinesIBA 03/01/1995 - "This study provides evidence to support the involvement of activated mononuclear cells, both T cells and monocytes and their secreted soluble products, cytokines, in the pathogenesis of Kawasaki disease." 05/01/2009 - "Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease." 07/01/2008 - "In the acute phase of Kawasaki disease, proinflammatory cytokines are elevated in serum and CSF. " 08/01/2007 - "The characterization of cerebrospinal fluid and serum cytokines in patients with Kawasaki disease." 04/01/2007 - "Polymorphonuclear leucocytes from patients with Kawasaki disease showed increased CD11b expression, which was associated with increased serum cytokines and appeared to be related to coronary artery lesions." Order ALL the reference details at left...
7.	Methotrexate (Mexate)FDA LinkGeneric 08/01/2002 - "We aimed to show in this study that methotrexate (MTX) may be used as a treatment for Kawasaki disease resistant to IVIG treatment. " 10/31/2008 - "Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease." 03/01/2005 - "Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate." 08/01/2002 - "A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate." 10/31/2008 - "PURPOSE: The aim of this study was to evaluate the efficacy of low-dose oral methotrexate (MTX) as a treatment for patients with Kawasaki disease (KD) which was resistant to intravenous immunoglobulin (IVIG). " Order ALL the reference details at left...
8.	infliximab (Remicade)FDA Link 07/01/2006 - "Efficacy of infliximab in long-lasting refractory Kawasaki disease." 08/01/2009 - "The regular evaluation of this cardiac biomarker after infliximab treatment may have clinical relevance in patients with refractory Kawasaki disease and severe heart involvement." 07/01/2009 - "Trends include increased numbers of admissions attributable to Kawasaki disease and increased usage of infliximab." 05/01/2007 - "Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab." 04/01/2004 - "Infliximab as a novel therapy for refractory Kawasaki disease." Order ALL the reference details at left...
9.	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 05/01/1993 - "Newer investigative procedures and therapeutic approaches have led to more accurate diagnoses and improved outcome but further advances await a better understanding of the vasculitides: polyarteritis; Kawasaki disease; Wagener's granulomatosis; and ANCA in childhood." 01/01/2007 - "We screened the sera of 148 MPO-ANCA positive patients from six vasculitic syndromes: rapidly progressive gromerulonephritis (RPGN), microscopic polyangiitis (MPA), idiopathic crescentic glomerulonephritis (I-CrGN), classic polyangiitis nodosa (cPAN), Churg-Strauss syndrome (CSS), Kawasaki disease (KD); and from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). " 10/01/1995 - "Vasculitis of small vessels found in our group of patients are concomitted by ANCA positivity in 90% (Wegener's granulomatosis 15/16, Churg--Strauss's syndrome 3/5, MPA 9/9), vasculitis of medium vessels 12% (classical polyarteritis nodosa 1/2, Kawasaki disease 0/2, Henoch--Schönlein's purpura 0/4, Takayasu's arteritis 1/4). " 09/01/1995 - "Anti-neutrophil cytoplasmic antibodies and anti-endothelial cell antibodies are not increased in Kawasaki disease." 03/01/2009 - "The diseases proven the efficacy of VIG by controlled trial were ITP, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multiple motor neuropathy, multiple sclerosis, myasthenia gravis, ANCA related vasculitis, Kawasaki disease, autoimmune uveitis and dermatomyositis. " Order ALL the reference details at left...
10.	Dipyridamole (Persantine)FDA LinkGeneric 03/01/2002 - "The aim of our study was to assess the ability of myocardial contrast echocardiography (MCE) with harmonic power Doppler imaging (HPDI) to identify perfusion abnormalities in patients with Kawasaki disease at rest and during pharmacological stress imaging with dipyridamole. " 11/01/1994 - "In the present study we assessed the effect of dipyridamole on the coronary arteries of patients with a history of Kawasaki disease by measuring the diameter of the coronary arteries and by quantifying the disappearance time of contrast medium (runoff time) on coronary angiography. " 09/01/1989 - "This study determined the feasibility and accuracy of quantitative 201Tl myocardial single-photon emission computed tomography (SPECT) after dipyridamole infusion to detect coronary obstructive lesions in children with Kawasaki disease. " 06/01/1984 - "Thus, thallium-201 myocardial imagings combining resting and exercise or dipyridamole studies were valuable for the detection and assessment of coronary arterial lesions of Kawasaki disease." 09/01/2005 - "To assess the alteration of myocardial ischemic findings and the role of collateral vessels in patients with Kawasaki disease (KD), we used dipyridamole stress technetium-99m tetrofosmin (Tf) single photon emission computed tomography (SPECT). " Order ALL the reference details at left...

Therapies and Procedures

1.	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 10/01/2001 - "BACKGROUND: The purpose of this study was to assess the long-term clinical outcome of coronary artery bypass grafting in pediatric patients with Kawasaki disease. " 07/07/2009 - "BACKGROUND: The long-term outcome of pediatric coronary artery bypass for patients with severe inflammatory coronary sequelae secondary to Kawasaki disease is unknown. " 07/07/2009 - "Twenty-five-year outcome of pediatric coronary artery bypass surgery for Kawasaki disease." 05/01/2009 - "The prevalence of coronary artery bypass grafting (CABG) based on the annual number of Kawasaki disease patients is 0.3-0.5% in Japan. " 07/01/2008 - "Off-pump beating coronary artery bypass grafting in a young adult with Kawasaki disease." Order ALL the reference details at left...
2.	Transplants (Transplant) 04/01/1990 - "Thus an internal mammary artery graft has proved to be satisfactory in the management of children with coronary artery obstruction caused by Kawasaki disease; it appears that both the quality of life and the life expectancy of those patients can be improved by the surgery." 09/01/1993 - " Coronary artery calcification also is well visualized, and coronary artery fistuli, coronary bypass graft patency, and Kawasaki disease can be assessed accurately using contrast-enhanced flow studies. " 11/01/2006 - "Redo off-pump coronary bypass grafting with arterial grafts for Kawasaki disease." 09/01/2006 - "Only the one patient who had Kawasaki disease died due to early primary graft failure. " 08/01/2002 - "Selective coronary angiography underestimates vasculopathy in transplant patients and intimal changes in Kawasaki disease. " Order ALL the reference details at left...
3.	Percutaneous Coronary Transluminal Angioplasty (PTCA) 05/01/2001 - "We successfully performed percutaneous transluminal coronary angioplasty (PTCA) in three infants with Kawasaki disease ages 11 to 29 months. " 05/01/2001 - "Feasibility of percutaneous transluminal coronary angioplasty to patients with Kawasaki Disease as an early management strategy." 05/01/2001 - "Has the time arrived for PTCA in CAD following Kawasaki disease?" 12/01/1998 - "Percutaneous transluminal coronary angioplasty in a child with Kawasaki disease." 05/01/1996 - "When the previously reported cases of six similar patients were taken into consideration, the only predictor of successful PTCA seemed to be the time elapsed between the onset of Kawasaki disease and performance of this procedure. " Order ALL the reference details at left...
4.	Intravenous Infusions 05/01/1994 - "Our findings indicate that p60 sTNF-R levels in serum may be useful for determining the severity of vascular damage during acute Kawasaki disease, and that patients with Kawasaki disease and high sTNF-R levels seem to be susceptible to coronary artery lesions even if they receive therapy with intravenous infusions of gamma-globulin." 01/01/2003 - "Intravenous infusion of vitamin C significantly increased the percent change in diameter of brachial artery induced by reactive hyperemia in 19 patients with history of Kawasaki disease (6.6 +/- 3.5 to 13.0 +/- 5.5%; P < 0.0001), whereas no significant increase was seen in the percent change in diameter of brachial artery induced by reactive hyperemia in 20 patients with history of Kawasaki disease after placebo administration (6.5 +/- 4.5 to 7.3 +/- 4.9%; P = 0.20). " 09/01/1994 - "We compared the efficacy of oral administration of pentoxifylline (PTX) and intravenous infusions of gamma globulin (IVGG) combination therapy with that of IVGG in reducing the frequency of coronary-artery lesions (CAL) in children with Kawasaki disease (KD), in a randomized trial. " 04/01/2003 - "BACKGROUND: High-dose intravenous infusions of immunoglobulin (IVIG) are well established as a standard therapy for Kawasaki disease (KD) for reducing the risk of coronary artery aneurysms. " 07/01/1998 - "A male infant, aged 2 month, with Kawasaki disease had a myocardial infarction despite intravenous infusions of gamma globulin and aspirin at high dosage. " Order ALL the reference details at left...
5.	Oral Administration 09/01/1994 - "We compared the efficacy of oral administration of pentoxifylline (PTX) and intravenous infusions of gamma globulin (IVGG) combination therapy with that of IVGG in reducing the frequency of coronary-artery lesions (CAL) in children with Kawasaki disease (KD), in a randomized trial. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Mucocutaneous Lymph Node Syndrome

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 61 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>